Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21617231 | 0.87 | MAPT (0.53) | MAPTSMN1; SMN2PPARGALDH1A1KDM4E | |
| SCHEMBL31504415 | 0.87 | MAPT (0.53) | MAPTSMN1; SMN2PPARGALDH1A1KDM4E | |
| SCHEMBL8127404 | 0.82 | KDM4E (0.59) | MAPTSMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL10870559 | 0.81 | MAPT (0.71) | MAPTSMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL11643791 | 0.79 | MAPT (0.78) | MAPTSMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL6793846 | 0.79 | KMT2A (0.62) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15411721 | 0.78 | MAPT (0.53) | MAPTSMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL15411938 | 0.78 | NPC1 (0.45) | MAPTSMN1; SMN2PPARGALDH1A1KDM4E | |
| SCHEMBL1141920 | 0.77 | MAPT (0.70) | MAPTSMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL4835421 | 0.77 | MAPT (0.70) | MAPTSMN1; SMN2ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48140-E1 | Furanone derivative | CARNA BIOSCIENCES, INC. (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2692728-B1 | NOVEL FURANONE DERIVATIVE | CARNA BIOSCIENCES INC (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-RE46815-E1 | Furanone derivative | CARNA BIOSCIENCES, INC. (JP) | 2018-05-01 | — | — | US | disclosed |
| US-8742113-B2 | Furanone derivative | SBI BIOTECH CO., LTD. (JP) | 2014-06-03 | — | — | US | disclosed |
| EP-2692728-A1 | NOVEL FURANONE DERIVATIVE | SBI Biotech Co., Ltd. (JP) | 2014-02-05 | — | — | EP | disclosed |
| US-20140018533-A1 | NOVEL FURANONE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018533-A1 | NOVEL FURANONE DERIVATIVE | CYP11B1, OXER1, CYP11B2 | MAPT 4591/4885SMN1; SMN2 3426/4885PPARG 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.